An observational study in Acute Kidney Injuries, Hemoglobin A1c Protein, Human and Coronary Bypass Graft Surgery, sponsored by Osman Sila Aydin. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Osman Sila Aydin · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Acute Kidney Injury with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Acute Kidney Injury · Turkey.
Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 22nd largest by planned enrollment of the 73 observational ones that give a count, is one of 18 that started in 2026, is one of 73 observational ones, reaches primary completion later than 7 of the 21 other live ones, and was the 66th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →21 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:
Namik Kemal University · Sites in Turkey
Ages 18+
AstraZeneca · Sites in Turkey, United States, Argentina and 11 more countries
Ages 18–80
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–80
Gaziosmanpasa Research and Education Hospital · Sites in Turkey
Ages 18+
CSL Behring · Sites in Turkey, United States, United Kingdom
Ages 12+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 108 across the 17 interventional studies, 130 across the 73 observational. Of the 61 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 90 have an industry lead sponsor. The 10 most frequent:
Osman Sila Aydin is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Osman Sila Aydin has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
12 of the studies in Acute Kidney Injury with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07635160Istanbul University - CerrahpasaAssessment of Renal Perfusion Using Ultrasound and Near-Infrared Spectroscopy in Patients Undergoing Minimally Invasive Abdominal Surgery | 2027-01-07 |
| NCT07918742Istanbul University - CerrahpasaDiastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy | 2027-01-31 |
| NCT07704242Medipol UniversityEarly Kidney Injury Biomarkers in Gynecologic Laparoscopic Surgery | 2027-02-01 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 90 studies in Acute Kidney Injury with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Renal complications are frequently encountered in cardiac surgery and constitute significant causes of morbidity and mortality. They most commonly present in the form of acute kidney injury (AKI). The etiological factors of AKI include hemodynamic alterations, hemolysis and pigment nephropathy, inflammatory response and cytokine storm, ischemia-reperfusion injury, use of nephrotoxic agents, patient-related risk factors (advanced age, diabetes mellitus, preoperative renal insufficiency, congestive heart failure, hypertension, anemia), duration of surgery, and postoperative complications such as low cardiac output syndrome, sepsis, bleeding and reoperation, hypoalbuminemia, and fluid imbalance.
Previous studies have demonstrated several mechanisms through which elevated HbA1c levels may contribute to acute renal injury, including glomerular damage and hyperfiltration, endothelial dysfunction and microvascular injury, tubular damage, accumulation of glycation products and advanced glycation end products (AGEs), structural changes in blood vessels, and metabolic and systemic factors.
The evaluation of acute renal failure relies on fundamental scoring systems, biomarkers, and imaging modalities. Among the scoring systems, the most current and widely used is the KDIGO (Kidney Disease: Improving Global Outcomes) classification. According to the KDIGO definition, the diagnosis of AKI can be established when at least one of the following three criteria is met: an increase in serum creatinine of ≥0.3 mg/dL within 48 hours, an increase in serum creatinine to ≥1.5 times baseline within 7 days, or a urine output of \<0.5 mL/kg/hour for more than 6 hours. AKI staging is performed based on these parameters.
Imaging modalities used in the assessment of renal function include renal ultrasonography (US), Doppler ultrasonography with measurement of the renal resistive index (RRI), renal MRI/MR angiography, and renal computed tomography (particularly CT angiography). RRI is a non-invasive, bedside-applicable method that provides direct information about renal vascular resistance by evaluating renal arterial flow patterns.
In our clinic, the rationale of the present study is to measure preoperative HbA1c and Doppler-derived RRI values in patients undergoing isolated coronary artery bypass surgery, and to evaluate their relationship with postoperative KDIGO classification and Doppler RRI values in order to gain insight into the development of AKI.
isolated coronary bypass graft surgery patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To evaluate the correlation between preoperative HbA1c Level, Doppler-Derived Renal Resistive Index (RRI), and development of acute kidney injury (KDIGO Criteria) after isolated coronary artery bypass grafting
Preoperative HbA1c Level; Glycated hemoglobin level will be measured from blood samples preoperatively. Unit of Measure: Percentage (%) Measurement Tool:Standard laboratory high-performance liquid chromatography (HPLC) assay Preoperative and Postoperative Renal Resistive Index(RRI) RRI will be measured using Doppler ultrasonography from segmental or interlobar renal arteries. Unit of Measure: Dimensionless ratio (RRI value) Measurement Tool: Doppler ultrasonography Normal Value Reference: RRI \< 0.70 Outcome Measure Title: Incidence of Acute Kidney Injury (KDIGO Criteria) Acute kidney injury will be assessed according to KDIGO criteria. Unit of Measure: Incidence of AKI (% of patients meeting KDIGO criteria) AKI Stage (Stage 1-3 classification) Measurement Tool: Serum creatinine measurement (mg/dL) Urine output monitoring Definition: Increase in serum creatinine ≥0.3 mg/dL within 48 hours OR increase to ≥1.5 times baseline within 7 days OR urine output \<0.5 mL/kg/hour for ≥6 hours
Time frame: Preoperative HbA1c Level Time Frame: Within 7 days prior to surgery Preoperative and Postoperative Renal Resistive Index (RRI) within 24 hours preoperatively and within 24 hours postoperatively KDIGO : 48 hours postoperatively,7 days postoperatively
To evaluate the correlation between preoperative HbA1c Level, Doppler-Derived Renal Resistive Index (RRI), and intensive care unit length of stay after isolated coronary artery bypass grafting
Length of Stay in the Intensive Care Unit Description:Duration of postoperative stay in the intensive care unit. Unit of Measure: Days Measurement Tool: Hospital electronic medical records
Time frame: Time Frame: From ICU admission after surgery until ICU discharge, up to one month
To evaluate the correlation between preoperative HbA1c Level, Doppler-Derived Renal Resistive Index (RRI), and hospital length of stay after isolated coronary artery bypass grafting
Total Hospital Length of Stay Description: Total duration of hospitalization following surgery. Unit of Measure: Days Measurement Tool: Hospital electronic medical records
Time frame: Time Frame: From date of surgery until hospital discharge, up to 3 month
To evaluate the correlation between preoperative HbA1c level, Doppler-Derived Renal Resistive Index (RRI), and duration of mechanical ventilation after Isolated coronary artery bypass grafting
Duration of Postoperative Mechanical Ventilation Description: Total duration of invasive mechanical ventilation following surgery. Unit of Measure: Hours Measurement Tool: Ventilator records and hospital electronic medical records
Time frame: From ICU admission after surgery until successful extubation, up to one month
Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.
Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 7 months is below that.
Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osman Sila Aydin